PubMed

What are the challenges of translating positive trial results in severe sepsis into clinical practice? A media roundtable debate, 18 March 2002, Brussels, Belgium.

Ball J.

Crit Care. 2002 Jun;6(3):271-4. Epub 2002 May 1.PMID: 12133192 [PubMed - indexed for MEDLINE]Related articlesFree article

Drotrecogin alfa (activated) for severe sepsis.

[No authors listed]

Drug Ther Bull. 2006 Jan;44(1):5-8. Review.PMID: 16425899 [PubMed - indexed for MEDLINE]Related articles

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

Reducing mortality in sepsis: new directions.

Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G.

Crit Care. 2002 Dec;6 Suppl 3:S1-18. Epub 2002 Dec 5. Review.PMID: 12720570 [PubMed - indexed for MEDLINE]Related articles

Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.

Wiedermann CJ, Kaneider NC.

Ann Med. 2004;36(3):194-203. Review.PMID: 15181975 [PubMed - indexed for MEDLINE]Related articles

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

Crit Care. 2006;10(3):R74. Epub 2006 May 9.PMID: 16684364 [PubMed - indexed for MEDLINE]Related articlesFree article

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A.

Crit Care. 2005;9(6):R607-22. Epub 2005 Sep 22. Review.PMID: 16280057 [PubMed - indexed for MEDLINE]Related articlesFree article

Recombinant human activated protein C for severe sepsis in neonates.

Kylat RI, Ohlsson A.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005385. Review.PMID: 16625638 [PubMed - indexed for MEDLINE]Related articles

Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.

Yan SB, Nelson DR.

Crit Care Med. 2004 May;32(5 Suppl):S239-46.PMID: 15118525 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

McCoy C, Matthews SJ.

Clin Ther. 2003 Feb;25(2):396-421. Review.PMID: 12749504 [PubMed - indexed for MEDLINE]Related articles

Inflammation and coagulation: implications for the septic patient.

Dellinger RP.

Clin Infect Dis. 2003 May 15;36(10):1259-65. Epub 2003 May 8. Review.PMID: 12746771 [PubMed - indexed for MEDLINE]Related articles

Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.

Sollet JP, Garber GE.

Am J Surg. 2002 Dec;184(6A Suppl):S11-8.PMID: 12521613 [PubMed - indexed for MEDLINE]Related articles

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

Short MA, Schlichting D, Qualy RL.

Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.PMID: 17265595 [PubMed - indexed for MEDLINE]Related articles

The use of activated protein C (drotrecogin alfa (activated)) in the treatment of severe sepsis.

Murgo M, Adamson H, Boyle M.

Aust Crit Care. 2003 Nov;16(4):133-43. Review.PMID: 14692158 [PubMed - indexed for MEDLINE]Related articles

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.PMID: 15774234 [PubMed - indexed for MEDLINE]Related articlesFree article

Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.

Liang J, Streat S, Torrance J, Sleigh J, Freebairn R, Ramsay M.

N Z Med J. 2003 Sep 12;116(1181):U586.PMID: 14581969 [PubMed - indexed for MEDLINE]Related articles

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.PMID: 17973539 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):7-9.PMID: 17323514 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.

Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D.

Eur J Anaesthesiol. 2008 Mar;25(3):211-6. Epub 2007 Nov 22.PMID: 18031590 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.

Bernard GR.

Crit Care Med. 2003 Jan;31(1 Suppl):S85-93. Review.PMID: 12544981 [PubMed - indexed for MEDLINE]Related articles